These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 8665528

  • 1. Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene.
    Li Y, White R.
    Cancer Res; 1996 Jun 15; 56(12):2872-6. PubMed ID: 8665528
    [Abstract] [Full Text] [Related]

  • 2. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M, Kishida S, Murai H, Hinoi T, Kikuchi A.
    Cancer Res; 1996 May 15; 56(10):2387-92. PubMed ID: 8625316
    [Abstract] [Full Text] [Related]

  • 3. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA, Cox AD.
    Oncogene; 2000 Sep 28; 19(41):4685-94. PubMed ID: 11032018
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V.
    Cancer Res; 1995 Aug 15; 55(16):3569-75. PubMed ID: 7627966
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J, Jiang B, Coffey RJ, Barnard J.
    Mol Cancer Res; 2004 Apr 15; 2(4):233-41. PubMed ID: 15140945
    [Abstract] [Full Text] [Related]

  • 10. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
    Bosch E, Cherwinski H, Peterson D, McMahon M.
    Oncogene; 1997 Aug 28; 15(9):1021-33. PubMed ID: 9285556
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells.
    Pollock CB, Shirasawa S, Sasazuki T, Kolch W, Dhillon AS.
    Cancer Res; 2005 Feb 15; 65(4):1244-50. PubMed ID: 15735008
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ras effector loop mutations that dissociate p120GAP and neurofibromin interactions.
    Stang S, Bottorff D, Stone JC.
    Mol Carcinog; 1996 Jan 15; 15(1):64-9. PubMed ID: 8561868
    [Abstract] [Full Text] [Related]

  • 16. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.
    Long IS, Han K, Li M, Shirasawa S, Sasazuki T, Johnston M, Tsao MS.
    Mol Cancer Res; 2003 Mar 15; 1(5):393-401. PubMed ID: 12651912
    [Abstract] [Full Text] [Related]

  • 17. Ras regulatory interactions: novel targets for anti-cancer intervention?
    Prendergast GC, Gibbs JB.
    Bioessays; 1994 Mar 15; 16(3):187-91. PubMed ID: 8166672
    [Abstract] [Full Text] [Related]

  • 18. Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells.
    Patel BK, Ray S, Whiteside TL, Kasid U.
    Mol Carcinog; 1997 Jan 15; 18(1):1-6. PubMed ID: 9022807
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.